Medicare Bundling Provisions Could Boost Affymax ESA in ESRD Arena
Executive Summary
Affymax sees the end-stage renal disease treatment bundling provisions in the Medicare Improvements for Patients and Providers Act as a potential opportunity for its new erythropoiesis stimulating agent to pull market share from Amgen's Epogen
You may also be interested in...
Affymax Swings $42 Million Financing To Push Hematide
Private/public infusion will see synthetic ESA through trials and approval.
Affymax Swings $42 Million Financing To Push Hematide
Private/public infusion will see synthetic ESA through trials and approval.
The Future Of ESAs – Is It All CKD Now?
Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.